Profilaxis de las infecciones en los pacientes neutropénicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue 10, 1997, Pages 544-551

  Capdevila, José Antonio ^a   Pahissa, Alberto ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CEFTAZIDIME; CIPROFLOXACIN; CLOTRIMAZOLE; COLISTIN; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NORFLOXACIN; NYSTATIN; OFLOXACIN; PEFLOXACIN; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIMANTADINE; UNINDEXED DRUG; VANCOMYCIN;

BACTEREMIA; BACTERIAL FLORA; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CROSS INFECTION; HUMANS; MYCOSES; NEUTROPENIA; PATIENT ISOLATION; VIRUS DISEASES;

EID: 0031461044     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (149)

1. Chang H-Y, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine 1976;55:259-268.
2. Brown AE. Neutropenia, fever and infection. Am J Med 1984;76:421-427.
3. Pizzo PA, Schimpff SC. Strategies for the prevention of infection in the myelosuppressed or immunosuppressed cancer patient. Cancer Treat Rep 1983;67:223-230.
4. Armstrong D. Infections in patients with neoplastic disease. En: Verhoef J, Paterson PK, Quie PG, editores. Infections in the immunocompromised host: pathogenesis, prevention and therapy. Amsterdam: Elsevier/Nort Holland Biomedical Press: 1980;129-170.
5. Bodey GP, Buckley M, Shate YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
6. Dale DC. Potential role of colony-stimulating factors in the prevention and treatment of infectious diseases. Clin Infect Dis 1994;18 (Supl 2): 180-188.
7. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Clin Infect Dis 1994;18 (Supl 2): 189-196.
8. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Gnauss J et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1.414-1.422.
9. Wingard JR, Elfenbein GJ. Host immunologic augmentation for the control of infection. En: Greene JN, Hiemenz JW, editores. Infectious diseases clinics of North América. Filadelfia: WB Saunders Company, 1996;10:345-364.
10. Schimpff S, Saterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;281:1.061-1.065.
11. Pizzo PA, Commers J, Cotton D, Gress J, Hathorn J, Miemenz J et al. Approaching the controversies in antibacterial management of cancer patients. Am J Med 1984;76:436-439.
12. Gurwith MJ, Brunton JL, Lank BA, Ronald AR, Harding GK. Granulocytopenia in hospitalized patients. I. Prognostic factors and etiology of fever. Am J Med 1978;64:121-126.
13. Verhoef J. Prevention etiology of infections in the neutropenic patient. Clin Infect Dis 1993;17 (Supl 2): 359-367.
14. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
15. Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK et al. Ceftiazidime versus imipenem-cilastin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1.335-1.337.
16. Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993;7:293-305.
17. Wade JC, Schimpff SC, Newman KA, Wjernik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1982;97:503-508.
18. Hathorn JW. Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts. Hematol Oncol Clin North Am 1993;7:1.051-1.064.
19. Whimbey E, Kiehn TE, Brannon et al. Bacteriemia and fungemia in patients with neoplastic disease. Am J Med 1987;82:723-728.
20. Bodey GP. Fungal infections complicating acute leukemia. J Crohn Dis 1966;19:667-675.
21. Meunier-Campentier F, Kieh TE, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-370.
22. Gold JWM. Opportunistic fungal infections in patients with neoplastic diseases. Am J Med 1984;76:458-464.
23. Brown AE. Overview of fungal infections in cancer patients. Semin Oncol 1980;17 (Supl 6): 2-15.
24. Klastersky J, Zinner SH, Calandra T, Gaya H, Glausser MP, Meunier F et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24 (Supl): 35-45.
25. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital changing frequency, earlier onset, and results of therapy. Rev Infec Dis 1985;7:646-655.
26. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989;8:323-330.
27. Bodey GP. Emerging antimicrobial-resistant pathogens in the immunocompromised host. Cur Op Infect Dis 1995;8:411-414.
28. Murphy ME, Sepkowitz KA, Armstrong D. Prevention of infection in patients with hematological malignancy. En: Wieor NIK, Kyle OA, Tatcher JP, editores. Neoplastic diseases of the blood (3a. ed.). Nueva York: Churchill Livingstone, 1996.
29. Rogers TR. Infections in hematologic malignancy. Infect Control 1986;7:140-143.
30. Wey S. Nosocomial infection in the compromised host. En: Wenzel RP, editor. Prevention and control of nosocomial infections (2a. ed.). Baltimore: Williams and Wilkins, 1993;923-957.
31. Donowitz GR. Infection prevention in the compromised host. En: Wenzel RP, editor. Prevention and control nosocomial infections. Baltimore: Williams and Wilkins, 1987;560-577.
32. Schimpff SC, Young VH, Greene WH, Vermeulen GP, Moody MR et al. Origin of infection in acute nonlymphocytic leukemia significance of hospital acquisition of potencial pathogens. Ann Intern Med 1972;77:707-714.
33. Nauseef VM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981;304:448-453.
34. Perry S, Penland WZ. The portable laminar flow isolator: new unit for patient protection in a germ-free environment. En: Mathe G, editor. Recent results in cancer research. Nueva York: Springer-Verlag, 1970;34-40.
35. Schimpff SC, Greene WH, Young VM, Fortner LL, Cusack N, Block JB et al. Infection prevention in acute nonlymphocitic leukemia: laminar air flow room reverse isolation with oral nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-358.
36. Body GP, Rodriguez V, Cabanillas F, Freireich EJ. Protected environment-prophylactic antibiotic program for malignant lymphoma: randomized trial during chemotherapy to induce remission. Am J Med 1979;66:74-81.
37. Ribas-Mundo M, Grañena A, Rozman C. Evaluation of a protective environment in the management of granulocytopenic patients: a comparative study. Cancer 1981;48:419-424.
38. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression a acute myelocytic leukemia patients. Cancer 1972;32:1.490-1.498.
39. Pizzo PA, Levine AS. The utility of protected environment regimens and antimicrobial decontamination a patients with high susceptibility to infection. Infection 1977;107:115.
40. Pizzo PA, Levine AS. The utility of protected-environment regimens for the compromised host: a critical assessment. En: Brown EB, editor. Progress in hematology. Nueva York: Grune & Stratton, 1977;311-332.
41. Bodey GP, Rodríguez V, Murphy WK, Burgess A, Benjamin RS. Protected environment-prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Cancer 1931;47:2.422-2.449.
42. Sheretz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987;83:709-718.
43. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989;14:89-95.
44. Storring RA, Jameson B, McElwain TJ, Witshaw E. Oral non-absorbide antibiotics prevent infection in acute non-lymphoblastic leukemia. Lancet 1977;2:837-840.
45. Watson JG, Jameson B. Antibiotic prophylaxis for patients in protective isolation. Lancet 1979;1:1.182-1.186.
46. Hanh DM, Schimpff SC, Fortner CL, Smyth AC, Young VM, Wierninck PM. Infection in acute leukemia patients receiving oral nonabsorbable antibiotics. Antimicrob Agents Chemother 1978;13:958-963.
47. Levine AS, Siegel SE, Schriber AD, Hauser J, Prewsler M, Goldstein IM et al. Protected environment and prophylactic antibiotics in a prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973;288:477-483.
48. Preisler HJ, Goldstein IM, Henderson ES. Grastrointestinal sterilization in the treatment of patients with acute leukemia. Cancer 1970;26:1.076-1.082.
49. Bodey GP, Rosenbaum B. Effect of prophylactic measures in the microbial flora of patients in protected environment units. Medicine 1974;53:209-217.
50. Levine AS, Gehan EA, Freireich EJ, Frei III E. Protected enviroment-prophylactic antibiotics: a prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973;288:477-484.
51. Lohner D, Debusscher L, Prevost JM, Klastersky J. Comparative randomized study of protected environment plus oral antibiotics versus oral antibiotics alone in neutropenic patient cancer treatment. Cancer Treat Rep 1979;63:363-367.
52. Haynes BW Jr, Hench ME. Hospital isolation system for prevention cross contamination by Staphylococci and Pseudomonas organisms in burn wounds. Ann Surg 1965;162:641-646.
53. Schimpft SC, Greene WH, Young VM, Fortner CL, Jensen L, Cusack N et al. Infection prevention in acute nonlymohocytic leukemia; laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-358.
54. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973;32:1.490-1.495.
55. Klastersky J, Debusscher L, Weerts D, Deeau D. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol (París) 1974;22:5-12.
56. Van der D Waaij D, Berghuis JM, Lekkerkerk JEC. Colonization resistance of the digestive tract in conventional and antibiotic-treated mece. J Hyg (Camb) 1972;69:405-411.
57. Hughes WT, Kuhn S, Chaudhany S, Feldman S, Verzosa A, Aur RS et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonia. N Engl J Med 1977;297:1.419-1.426.
58. Gurwith MJ, Brunton JL, Lank BA, Harding GKM, Ronhd A. A prospective controlled investigation of prophylactic trimethroprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248-254.
59. Estey E, Maksymiuk A, Smith T, Fainstein V, Heating M, Mc Credie KB et al. Infection prophylaxis in acute leukemia comparative effectiveness of sulfamethoxazole and trimetroprim, ketoconazole, and a combination of the two. Arch Intern Med 1984;144:1.562-1.568.
60. Henry SA. Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am J Med 1984;67:645-650.
61. Kauffman CA, Leipman MK, Bergman AG. Mioduszewski J. Trimethoprim sulfamethoxazole prophylaxis in neutropenic. Am J Med 1983;74:599-608.
62. EORTC International Therapy Project Group. Trimethorpim sulfamethoxazole prophylaxis in the prevention in neutropenic patients. J Infect Dis 1984;150:372-378.
63. Henry SA, Armstrong D, Kempin S, Gee T, Arlin L, Clarkson B. Oral trimethoprim/sulfamethoxazole in an attempt to prevent infection after reduction chemotherapy for acute leukemia. Am J Med 1984;77:663-667.
64. Enno A, Darrell J, Howns J, Cotawsky D, Galton DA, Goldman JM. Co-trimoxazole for prevention of infection in acute leukemia. Lancet 1978;2:395-397.
65. Bavisotto L, Maky DG. Does TMP-SMX profilaxis in acute non-lymphocytic leukemia (ANLL) predispose to fungal infection? Clin Res 1981;29:726A.
66. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987;106:7-12.
67. Wilson JM, Guiney DJ. Failure of oral trimethroprim prophylaxis in acute leukemia-isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteriemia. N Engl J Med 1982;306:16-21.
68. Bow EJ, Rayner E, Luie TJ. Comparison of norfloxacin with citromoxazole for infection prophylaxis in acute leukemia: trade off for reduced gram-negative sepsis. Am J Med 1988;84:847-854.
69. Liang RH, Young RWH, Chan TW, Chau PY, Lam WK, So SY et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 1990;34:215-218.
70. Jansen J, Cromer M, Akard L, Black JR, Wheat LJ, Allen SD. Infection prevention in severity myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med 1994;96:335-341.
71. Winston DJ, Ho WG, Nakao SL; Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1986;80:884-890.
72. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bammerger BJ et al. Norfloxacin for prevention of gramnegative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987;:1-7.
73. Talcott JA, Finberg R, Mayor RL, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2.561-2.568.
74. Malik IA, Khan WA, Aziz Z, Karim M. Self-administered therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 1994;19:522-527.
75. Cruciani M, Concia E, Navarra A, Perversi L, Bonetti F, Arllo M et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children-prospective randomised study. Infection 1989;17:65-70.
76. Lew MA, Kehoe K, Ritz J, Antman KM, Naddler L, Takvorian T. Prophylaxis of bacterial infections with ciprofloaxin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-636.
77. Lopez A, Soler JA, Juliá A, Novo A, Bueno J. Profilaxis con ciprofloxacino en la neutropenia posquimioterápica de la leucemia mieloide aguda. Med Clin (Bare) 1994;102:81-85.
78. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/prolyxin for prevention of infections in granulopenic patients. Am J Med 1990;88:36-42.
79. The GIMENA Infection Program. Prevention of bacterial infection in neutropenic patients with haematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991;115:7-12.
80. Gilbert C, Meisenberg B, Vrederburg J, Ross M, Hussein A, Perfect J et al. Sequential prophylactic oral empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and outologous bone marrow support. J Clin Oncol 1994;12:1.005-1.011.
81. Cornetta A, Calandra T, Bille J, Glauser MR Emergence of fluoroquinolone-resistant blood isolales in granulocytopenic cancer patients given fluoroquinolone prophylaxis. En: Orlando: Program and Abstracts, 34th Interscience Conference on Antimicrobial Agents and Chemoterapy, 1994 [resumen E30].
82. Carratalà J, Fernández de Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receivoing norfloxacin profilaxis. Antimicrob Agents Chemother 1996;40:503-505.
83. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteriemia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA 1994;272:1.183-1.189.
84. Warren RE, Wimperis JZ, Baglin TP, Constantine CE, Marcus R. Prevention of by ciprofloxacin in neutropenia. J Antimicrob Chemother 1990;26 (Supl F): 109-123.
85. Rozenberg-Arska M, Dekker AW, Verdomck LF, Verhoef J. Prevention of bacteriemias caused by a-hemolytic streptococci by roxithromycin in patients treated with intensive cytoloxic treatment. Infection 1989;17:240-244.
86. Hidalgo M, Hornedo J, Lumbreras C.Trigo JM, Gómez C, Perea S et al. Lack of ability of ciprofloxacin-rifampicin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother 1997;41:1.175-1.177.
87. Cruciani M, Rampazzo R, Melena M, Lazzarini L, Todeschini G, Messori A et al. Concia E. prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805.
88. Bow EJ, Mandell LA, Louie TJ, Feld R, Palmo M, Tee B et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996;125:183-190.
89. Centers for Disease Control. Interim guidelines for prevention and control of sataphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997;46:626-635.
90. Krick J, Remington J. Opportunistic fungal infections in patients with leukemia and lymphoma. Clin Haematol 1976;5:249-260.
91. Rostein C, Cumming KM, Tidings J. An outbreak invasive aspergillosis armong allogenic bone marrow transplants: a case controlled study. Infect Control 1985;6:347-355.
92. Lentino JR, Rosenkranz MA, Michaels JA, Kurup UP, Rose HD, Ryrel MW. Nosocomial aspergillosis: a retrospective review of airbone disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982;16:430-437.
93. Rose HD. Mechanical control of hospital ventilation and Aspergillus infections. Am Rev Respir Dis 1972;105:306-311.
94. Aisner J, Schimpff SC, Bennett JE, Young VM, Wiernik PH. Aspergillus infections in cancer patients: association with fireproofing materials in a new hospital. JAMA 1976;235:411-416.
95. Sarubbi FA, Kopf HB, Wilson MB, McGinnis MR, Rutala WA. Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis 1982;125:33-38.
96. DeGregorio MW, Lee MW, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1932;50:2.780-2.784.
97. Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984;144:549-554.
98. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-897.
99. Tollemar J, Ringden O, Anderson S, Sundherg J, Lsurgman P, Sparrelid E. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1.495-1.497.
100. Owens NJ, Nightingale CH, Schweizer RT, Schauer Pk, Dekker PT, Quintiliani R. Prophylaxis of oral conditions with clotrimazole troches. Arch Intern Med 1984;144:290-293.
101. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canadá-Clinical Trials Group. Vancomycin added to empirical combination antibiotic for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-957.
102. Cuttner J, Troy KM, Funaro L, Brendon R, Bottone EJ. Clotrimoxazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy: results of a double-blind study. Am J Med 1986;81:771-774.
103. Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987;83:1.1-1.1.
104. Hansen RM, Reinero N, Sohnle PG, Abrams RA, Rich DS, Lianola SA. Ketoconazole in the prevention of candidiasis in patients with cancer. Arch Intern Med 1937;147:710-715.
105. Palmblad J, Lonnqvist B, Carlsson B, Grimfors G, Jarnmark M, Lerner R et al. Oral ketoconazole prophylaxis for Candida infections during reduction therapy for acute leukemia in adults: more bacteremias. J Intern Med 1992;231:363-370.
106. Hann IM, Corringham R, Keaney M, Noone P, Fox J, Slawatkowski M et al. Ketoconazol versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-829.
107. Shepp DH, Klosterman CA, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infections in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1.285-1.291.
108. Turhan A, Connors JM, Klimo P. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemortherapy. Am J Clin Oncol 1987;10:355-358.
109. Donnelly JP, Starke ID, Galton DAG, Catowsky D, Goldman JM, Darrell JH. Oral ketoconazol and amphotericin B for the prevention of yeast colonization in patients with acute leukemia. J Hosp Infect 1984;5:53-88.
110. Schaffner A, Frick PG. The effect of ketoconazole or amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985;151:902-910.
111. Sud LJ, Feingold DS. Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob Agents Chemother 1983;23:185-187.
112. Brammer KW, Farrow PR, Faukner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12 (Supl): 318-323.
113. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
114. Winston DJ, Chandrasakar PH, Lazarus HM, Goodman JL, Silber JL, Herowitz H et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
115. Ninane J. Multicentre Study Group: a multicentre of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 1994;13:330-337.
116. Abi-Said D, Anaissie E, Uzum O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematologous candidiasis by different Candida species. Clin Infect Dis 1997;24:1.122-1.128.
117. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987;9:408-416.
118. Garant SM, Clissold SP. Itraconazole: a review if its pharmacodynamic and pharmacokinetic properties and therapeutic uses in superficial and systemic mycoses. Drugs 1989;37:310-322.
119. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH et al. NAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-144.
120. Prentice AG, Warock DW, Johnson SAN, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34:247-251.
121. Tricot G, Joosten J, Boogaerts MA, Van de Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of nonrandomized studies. Rev Infect Dis 1987;9 (Supl 1): 94-99.
122. Boogaerts MA, Verhoef GE, Zachee P, Demuynek H, Verbist L, De Beule K et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia correlation with plasma levels. Mycoses 1989;32 (Supl 1): 103-108.
123. Todeschini G, Murai C, Bonesi T, Piccolo J, Amaddi G, Ambrosetti S et al. Oral itroconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;12:614-618.
124. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;91:484-492.
125. Meunier-Carpentier F, Snoeck R, Gerain J, Mueller C, Klastersky J. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. N Engl J Med 1984;311:1.056-1.060.
126. Jeffery GM, MEJ, Ikram RB, Chua J, Allen JR, Heaton AC et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991;90:685-692.
127. Conneally E, Cafferkey MT, Daly PA, Keane CT, Mc Cann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990;5:403-408.
128. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated inmunity after marrow transplant. J Infect Dis 1980;142:338-346.
129. Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ et al. Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients: a randomized, double-blind placebo controlled study. Ann Intern Ned 1983;99:773-379.
130. Bustamante CI, Wade JC. Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991;9:1.903-1.915.
131. Yousuf HM, Englund J, Couch R, Rolsnon K, Luna M, Goodrich J et al. Influenza A among hospitalized adults with leukemia. Clin Infect Dis 1997;24:1.095-1.099.
132. Wimbey E, Bodey GP. Viral pneumonia in the immunocompromised adult with neoplasic disease: the role of common community respiration viruses. Sem Respir Infect 1992;7:122-131.
133. Wimbey E, Couch RB, Englund JA, Andreef M, Goodrich JM, Raad II. Respiratory sincitial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995;21:376-379.
134. Centers for Disease Control and Prevention. Prevention and control of influenza: recomendations of the Advisory Committee on Inmunization Practices (ACIP). MMWR Morb Mortal Weekly Rep 1995;44 (Supl RR-3): 1-22.
135. French JE, Solomon JM, Fratantoni JC. Survey on the current use of leukophoresis and collection of granulocyte concentrates. Transfusion 1982;22:220-226.
136. Rosenshein MS, Farawell VT, Price TH, Larson EB, Dale DL. The cost effectiveness of therapeutic and prophylactic leukocyte transfusion. N Engl J Med 1980;302:1.058-1.064.
137. Ford JM, Cullen MH. Prophylactic granulocyte transfusions. Exp Hematol 1977;5:65-72.
138. Schiffer CA, Aisner J, Daly PA, Schimpff SL, Wiernik PH. Alloinmunization following prophylactic granulocyte transfusion. Blood 1979;54:766-770.
139. Clift RA, Sanders JE, Thomas ED, Williams B, Buckner CD. Granulocyte transfusions for the prevention of infections in patients receiving bone-marrow transplants. N Engl J Med 1978;298:1.052-1.057.
140. Vadham-Raj, Broxmeyer HE, Hittelman WN, Papadopoulus NE, Chawla SP, Feroglio C et al. Abrogating chemotherapy-induced myelosupression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992;10:1.266-1.277.
141. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Maillard JA et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997;336:1.776-1.780.
142. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997;336:1.781-1.787.
143. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C. Granulocyte colony stimulating factor after allogenic bone marrow transplantation. Blood 1994;84:1.680-1.684.
144. Hamm JT, Schiller JH, Oken MM. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCCL): preliminary analisis of a randomized controlled trial [resumen]. Proc Am Soc Clin Oncol 1991;10:255.
145. Wellenga E, Uyl-de Groot CA, De Witt R, Keizer HJ, Lowemberg B, Ten Haaf MA et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996;14:619-627.
146. Body GP, Anaissie E, Gutterman J, Vadham-Raj S. Role of granulocyte-macrophage colony-stimulating factors as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 1994; (Supl 2) 18-22.
147. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors. Evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1.957-1.960.
148. Hoeltzer D. Haematopoietic growth factors-not whether, but when and where. N Engl J Med 1997;336:1.822-1.824.
149. Tersptra W, Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997;11:315-327.